Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rugonersen in Angelman Syndrome
NCT07605429Phase 3Recruiting
- Sponsor
- OHB Pediatrics
- Start
- Jun 2026
- Primary completion
- Mar 2029
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 2
01
Overview
A Phase 3 trial of rugonersen in Angelman syndrome (AS), sponsored by OHB Pediatrics. Started Jun 2026; status: recruiting.
02
Drugs
rugonersen
03
Conditions
Angelman syndrome (AS)
Beyond the preview
Go deeper on NCT07605429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07605429.